200 related articles for article (PubMed ID: 21431628)
1. Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
Font P
Adv Ther; 2011 Mar; 28 Suppl 3():1-9. PubMed ID: 21431628
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloblastic leukemia.
Molina CA; Rodríguez MJ; de Marcos NS; Font P
Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
[TBL] [Abstract][Full Text] [Related]
4. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
5. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2009; 69(17):2501-18. PubMed ID: 19911860
[TBL] [Abstract][Full Text] [Related]
12. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
14. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
15. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
17. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
18. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
